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Abstract
Background: There is lack of population level data on prevalence and distribution of common benign women’s
health conditions such as endometriosis, uterine fibroids, polycystic ovary syndrome from the Eastern Mediterranean
region despite their significant consequences on quality of life. In particular, there is complete absence of any health
statistics from Northern Cyprus, which is an emerging region in Europe. The Cyprus Women’s Health Research
(COHERE) Initiative is the first large-scale cross-sectional study in the region, aiming to determine the relative burden of
benign women’s health conditions and related co-morbidities in women living in Northern Cyprus.
Methods: The COHERE Initiative is a cross-sectional study aiming to recruit 8000 women aged 18–55 years and residing
for at least the past 5 years in Northern Cyprus. The study is composed of two main steps: (1) Baseline recruitment,
including (i) completion of a detailed health questionnaire, which is an expanded version of the World Endometriosis
Research Foundation (WERF) Endometriosis Phenome Harmonisation Project (EPHect) standardised questionnaire,
including questions on demographics, menstrual history, hormone use, pregnancy, pain (pelvic pain, bladder and bowel
pain, migraine), medical history, family history of illnesses, medication use, life-style factors in relation to a wide range of
reproductive and endocrine conditions, resource use (ii) measurement of weight, height, waist/hip circumference and
blood pressure, (iii) collection of saliva samples for genotyping. (2) Gynaecology clinic follow up, including a pelvic
ultrasound scan (USS). There is also a follow-up food frequency questionnaire (FFQ) targeted to all women taking part in
the baseline recruitment with an aim to collect more detailed data on dietary habits.
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Discussion: The COHERE Initiative will generate prevalence rates for conditions, define the clinical profiles for women’s
health conditions, and estimate the economic burden of these conditions in Northern Cyprus. The results will also
provide insights into the current status of health-care among women living in a currently under-investigated region. The
genetic findings will inform future gene mapping studies for investigation of the heritable component of conditions in
this population/region. Moreover, the results will be compared with other centres collecting data using EPHect tools
globally and will help determine population differences and similarities in disease patterns and clinical profiles. The
COHERE Initiative will serve as a resource to conduct hypothesis-driven follow-up studies investigating effect of the
‘Mediterranean life-style’ as well as genetic factors on common benign women’s health conditions that maybe specific
to Eastern Mediterranean populations.
Keywords: Benign women’s health conditions, Prevalence, Endometriosis, Uterine fibroids, PCOS, Chronic pain
conditions, Eastern Mediterranean population
Background
Cyprus is the third largest Mediterranean island with
approximately 300,000 Turkish Cypriot and 700,000
Greek Cypriot residents. Due to the, to date, unresolved
political circumstances, Northern Cyprus, has been
relatively isolated from the rest of Europe for more than
45 years [1]. Although Cyprus has been a member of the
European Union (EU) since May 1, 2004, the acquis
communautaire is suspended in the northern part of the
island [2], and unfortunately official collaborations
between the north and south administrations and insti-
tutions have been absent. Consequently, population-level
health data from Northern Cyprus have not been in-
cluded in health statistics reported for Cyprus [3]. More-
over, there is an absence of population-level data on
common benign women’s health conditions such as
endometriosis, uterine fibroids, polycystic ovary syn-
drome (PCOS) and related co-morbidities generally
from the Eastern Mediterranean region. It is well
established that women’s cohorts such as the Nurses’
Health Study from the USA [4] and the Million
Women Study from the UK [5] have been crucial in
investigating how various reproductive and lifestyle
factors affect women’s health. Hence, establishment of
a resource to investigate women’s health conditions
and causal environmental and genetic factors that can
be specific to populations is necessary for the Eastern
Mediterranean populations.
The Cyprus Women’s Health Research (COHERE)
Initiative aims to establish a women’s health cohort in
Cyprus, with current emphasis on the north for the
above-mentioned reasons of data paucity to collect vital
health, morbidity, and resource use data, and investigate
factors affecting women’s health and care seeking.
COHERE Initiative is a population-based, cross-sectional
study, based on a household/workplace sampling
method utilising an extended version of the Endometri-
osis Phenome and Biobanking Harmonisation Project
(EPHect) questionnaire [6–11] that consists of validated
instruments used in previous studies, targeting 10%
of all women aged 18–55 (N = 8000) living in
Northern Cyprus. Study participants completing the
questionnaire also have the opportunity to provide a
saliva sample for genotyping to understand the
underlying genetic architecture of this population.
Moreover, participants are invited to a clinical
follow-up visit at a women’s health clinic that in-
cludes a transvaginal or transabdominal pelvic ultra-
sound scan (USS) that provides clinical data on
diagnosis of uterine fibroids, polycystic ovaries, and
some endometriosis cases.
This study will provide the first systematically col-
lected population health data for Northern Cyprus - an
emerging region in Europe for which public health is-
sues have been unexplored to date. The study will aid
the understanding of regional women’s health and illness
patterns, and the personal, social and economic burden
of symptomatology and disease. Disease rates, clinical
profiles, and healthcare statistics of women in this popu-
lation will be utilised to assess the relative burden of
disease, and results will form the basis for targeted
hypothesis-driven follow-up studies. Moreover, the
Cypriot adaption of the ‘Mediterranean lifestyle’ allows
for investigation of the influence of both environmental
as well as genetic factors specific to Eastern Mediterra-
nean populations. With this study, the genetic architec-
ture of the population will be unravelled to better
inform future gene association studies, investigating
genetic risk variants for disease/traits from this popu-
lation. Moreover, given the genetic susceptibilities, it
will lay the foundation to promote changes in poten-
tial environmental modifiers for common complex
women’s health conditions in the region. Furthermore,
the health statistics that will be generated from the
study will inform the health authorities about preva-
lence and distribution of certain women’s health is-
sues that can be used in development of data-driven
health strategies in the region.
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Method/design
Study aims
This study aims to (1) estimate prevalence rates of
gynaecological conditions and associated symptomatol-
ogy, auto-immune, inflammatory, metabolic and pain
co-morbidity profiles; (2) investigate how various repro-
ductive and lifestyle factors affect women’s health includ-
ing diet, exercise, employment patterns, oral contraceptive
use, childbirth and breastfeeding, family history of illness,
in relation to a wide range of reproductive and endocrine
conditions, (3) investigate the geospatial distribution of
identified conditions in Northern Cyprus and also com-
parison of disease rates with other 19 centres collecting
data using EPHECT based data collection tool, (4) under-
stand the genetic architecture of this population by
genotyping DNA extracted from saliva samples collected
from a minimum of 1000 participating women, (5) quan-
tify women’s access to health care and estimate the
economic burden of diseases such as endometriosis in
Northern Cyprus, (6) gain insights into women’s percep-
tions of research and interest in participation in subse-
quent follow-up studies.
Ethics
The study was approved by the Oxford Tropical Re-
search Ethics Committee (OxTREC) of the University of
Oxford (OxTREC reference: 37–17). The study also re-
ceived local ethics approval from the Eastern Mediterra-
nean University Ethics Committee (ETK00-2017-0240).
Eligibility
Women aged 18 to 55 years, who are either citizens of
Northern Cyprus or have been residing in Northern
Cyprus for the last 5 years, and who are able to give in-
formed consent are eligible to participate in the study.
Women younger than 18 or aged over 55, non-citizen
women who have been residing in Northern Cyprus for
less than 5 years, women who cannot understand the
information on the participant information sheet or
informed consent form due to being very unwell or
illiterate will be excluded from the study.
Recruitment procedures
Participants are recruited through two different routes
(Fig. 1): (i) Face-to-face recruitment where household/
workplace visits are conducted by the research assis-
tants to inform the women about the study and invite
them to participate in the study. If women are inter-
ested in taking part, they provide informed consent
and then complete the questionnaire. Additionally,
they have the option of providing a saliva sample
and/or undergoing an appointment at the women’s
health clinic for a pelvic USS. (ii) Online recruitment,
which is promoted through dedicated social media
(https://web.facebook.com/KISAAInisiyatifi) page and
study page (http://www.cohereinitiative.com). Partici-
pants can anonymously complete the study question-
naire online. At the beginning of the questionnaire,
they read the participant information sheet and
complete an online consent. At the end of the online
questionnaire, if they would like the opportunity to
take part in the clinical follow-up or provide saliva
samples, they are instructed to call the research assis-
tants, using their assigned study participant codes
from the online questionnaire. The research assistants
arrange an appointment to meet the participant
face-to-face to complete a written consent followed
by saliva sample collection and/or scheduling of the
women’s health clinic appointment.
Study design
COHERE Initiative is a population-based cross-sectional
study composed of two main steps (Fig. 1): (i) Baseline
assessment includes informing participant, getting
consent, collecting of questionnaire-based health and
lifestyle data, taking anthropometric measurements, col-
lecting saliva sample for DNA extraction and genotyp-
ing, (ii) Clinical follow-up includes a pelvic USS by an
experienced gynaecologist.
Baseline assessment
All women are informed about the study and the
consenting women are given a unique participant ID to
be used throughout the study. Participants are asked to
complete the baseline EPHect-based health questionnaire
[10] with validated instruments used in previous studies
either on paper or on tablet computer (Additional file 1).
The questionnaire takes around 20–30min. After the
completion of the baseline health EPHect-based question-
naire, basic anthropometric measurements are taken from
consenting women. A saliva sample is collected for DNA
extraction from a subset of the consenting women. As the
last item on the baseline assessment, women are provided
with the food frequency questionnaire (FFQ) [12–14],
which they can complete in their own time. There are two
options to complete the FFQ: (1) Online, using their
unique participant ID, they can login to complete FFQ
with the given questionnaire web-link, (2) Paper-based, on
which the research assistants put a sticker with the
unique participant ID and hand the questionnaire to
the participant to complete in their own time and
drop their FFQ to the near-by questionnaire collec-
tion boxes. Clinical appointments for the consenting
participants are given by the research assistant at the
end of the baseline assessment at most within 2 weeks
of their baseline assessment.
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Clinical follow-up
At the clinical follow-up, participants undergo a pelvic
USS performed by an experienced gynaecologist. Ideally,
this is a transvaginal procedure but can be transabdom-
inal if preferred by the participant. As well as being
linked to the unique participant ID, scan reports are also
provided to the participant in the form of a medical
report.
Data collection tools
Expanded EPHect-based health questionnaire
Each consenting woman is asked to complete the
EPHect-based health questionnaire. EPHect consists of a
set of tools to standardise globally the collection of
clinical/lifestyle data and samples across studies to allow
for more effective large-scale international collaborative
research studies on endometriosis. We have utilized the
EPHect health questionnaire as the basis of this study
questionnaire and expanded it to capture data on other
benign women’s health conditions such as uterine fi-
broids, polycystic ovary syndrome, various chronic pain
conditions such as bladder pain and migraine, endocrine
conditions such as thyroid conditions. The questionnaire
was translated into Turkish, and then back-translated
into English. Differences between the original English
version and translated English version were compared
by an expert panel. The Turkish version was revised
where there were differences. The Turkish version was
piloted in 100 Turkish Cypriot women of different age
segments (Ages: 18–30; 30–40; 40–55) and education
levels (Highest education attained: primary school
diploma; high school diploma; university degree). Com-
ments from the participants for any unclear questions
were also incorporated to the final version. For the
Fig. 1 Overview of the study design
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Turkish validated and published versions of the ques-
tionnaire, scales were identified and incorporated into
the questionnaire including the SF36 v2 [15] and Pain
Catastrophizing Scale [16].
Measurements
Research assistants take blood pressure, weight, height,
waist and hip circumference measurements. Each meas-
urement is taken twice; where there is a significant
difference between the two measurements, a third meas-
urement is also taken.
Saliva collection kits
Saliva samples are collected for DNA extraction for
genotyping [17–19]. A total of 2 ml of saliva sample is
collected by the participant actively spitting into an
ORAGENE-saliva collection tube. The standard oper-
ation protocol that comes with the saliva collection kit is
followed by each participant and overseen by the re-
search assistant. This is a risk-free, non-invasive method
for high-quality DNA extraction from saliva samples.
Food frequency questionnaire
The last item on the baseline assessment is to provide
women with the Food-Frequency Questionnaire (FFQ),
which they can complete in their own time. The
semi-quantitative food frequency questionnaire that has
been validated for use in Turkish adults [12] is utilised
for this cohort of women, and has also been used in a
global study previously [13, 14].
Pelvic ultrasound scan (USS)
Either a transvaginal or transabdominal pelvic USS is
conducted on consenting women at the clinical
follow-up to examine their reproductive organs. The
pelvic USS results provide clinical data on diagnosis of
uterine fibroids, polycystic ovaries and some of the
endometriosis cases. Both transvaginal and transabdom-
inal USS are safe, risk-free tests routinely conducted in
gynaecology clinics. Pelvic USS uses high-frequency
sound waves (no radiation) to create images of the fe-
male reproductive organs and the pelvic cavity. Some
participants may find transvaginal scans uncomfortable
since it involves the transducer being inserted into the
vagina and this would be inappropriate for women who
are virgo intacta. Therefore, as an alternative, we are of-
fering a transabdominal USS where the transducer
moves only over the abdomen to image the pelvis.
Statistical analysis
Data analysis will commence after the data collection
period (January 31, 2018-January 31, 2020) ends.
Descriptive statistics including characterisation of the
women participating in the study will be provided where
the prevalence rates (and 95% confidence intervals)
for self-reported and clinically validated medical con-
ditions will be estimated. Association of life-style
factors and various symptomatology between deter-
mined disease case groups and healthy controls will
be investigated using the statistical computing soft-
ware package R.
The open-source geographic information system plat-
form QGIS (Open Source Geospatial Foundation) will
be used to visualise data. Spatial and/or temporal clus-
tering among the investigating conditions and symptom-
atology will be explored and Geographically Weighted
Regression (GWR) analysis [20] will be performed to in-
vestigate hidden relationships among the conditions and
symptomatology with regards to geospatial distribution.
Quality control of the genetic data will be conducted
using PLINK software [21] followed by cluster analysis
such as principal component analysis, implemented in
R, to identify individuals with ancestral differences that
will aid future studies aiming to investigate the genetic
background of conditions/traits [22]. Moreover, genetic
association analysis, where large enough sample sets are
present, using linear and logistic regression modelling
for quantitative and qualitative traits respectively, will be
conducted comparing the differences in frequency and
distribution of genetic variants.
Furthermore, the economic burden of disease will be
estimated using direct and indirect costs.
Power calculations
We are aiming to recruit a random ~ 10% sample of the
82,104 women between the ages of 18–55 residing in the
5 main regions of in Northern Cyprus including Lefkosa,
Girne, Gazimagusa, Guzelyurt and Iskele following the
geographic population densities. The aimed total sample
size of 8000 women will allow us to detect prevalence
rates as low as 0.5% in the overall population (40 cases:
7960 controls). Moreover, it will also allow us to
estimate prevalence rates as low as 1% in the most popu-
lated cities such as Lefkosa and Gazimagusa (target
recruitment of 2716 and 1981 women respectively), and
in comparison, in the less populated regions such as
Guzelyurt (target recruitment of 808 women) a preva-
lence rate of 2% and in smaller rural villages, prevalence
rates of 5–10% will be estimable. Please see the
Additional file 2: Power calculations for details of the
sample size calculations and recruitment targets for each
region. Moreover, where we have the needed case num-
bers, we aim to look for association between lifestyle
factors and conditions. For example, the overall sample
size of 8000 allows for detection of 2–16% increase in
exposure rates in cases compared to controls, where
disease prevalence rates are 1–50% and exposure rates
in controls are 10–90%.
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Data management
All study data will be entered on a custom-made
cloud-based survey platform maintained by our study
technology funder DMD consulting with servers
employing secure cloud computing environment located
in Frankfurt, Germany. The cloud-based data are se-
curely transferred to high-compliance University of
Oxford servers on a monthly basis. Direct access will be
granted to authorised representatives from the Univer-
sity of Oxford and any host institution for monitoring
and/or audit of the study to ensure compliance with
regulations.
The participants will be identified by a unique partici-
pant ID number in the database and nowhere in the
electronic database, patient identifiable data are to be
stored. Paper records (including consent forms) will be
held in locked cabinets in the Chief Investigator’s office
at Eastern Mediterranean University during data collec-
tion. After data collection is finished, these will be trans-
ferred to University of Oxford premises and stored in a
locked cabinet at the University of Oxford until 31st
January, 2028 (end date of the study) and archived for
another 10 years after the completion of the study.
Discussion
This study is the first population-based study that will
collect data in a standardized way allowing for investiga-
tion of women health conditions, related co-morbidities
and symptomatology from an Eastern Mediterranean
population. The unique setting of the target Turkish
Cypriot population will also provide critical insights into
the successes and disparities of health-care among
women living in an internationally under-represented
community that may be applicable across the globe.
The standardised data collection tools utilised in the
study will allow for comparison of disease rates, clinical
profiles, and healthcare statistics of women in this popu-
lation with at least 19 other EPHect centres globally
(https://endometriosisfoundation.org/ephect/) to better
understand the relative burden of disease.
Moreover, the results of this study will form the
basis for targeted, hypothesis-driven follow-up studies.
They will facilitate addressing of the environmental
factors, such as diet as well as the genetic factors
causal for women’s health conditions that may be
specific to Eastern Mediterranean populations. The
genetic architecture of women in Northern Cyprus
will be revealed to better inform future genetic
association studies.
This study is envisaged to promote evidence-based
reproductive medicine in the region, not only benefitting
the local population but also providing a basis for an
Eastern Mediterranean women’s health resource.
Additional files
Additional file 1: Baseline study questionnaire. (PDF 710 kb)
Additional file 2: Power calculations. (DOCX 15 kb)
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